AccueilCVM • NYSEAMERICAN
add
CEL-SCI Corp
0,90 $
Après la clôture :(0,33 %)+0,0030
0,90 $
Fermé : 18 oct., 18:54:17 UTC−4 · USD · NYSEAMERICAN · Clause de non-responsabilité
Dernière clôture
0,95 $
Variation sur la journée
0,89 $ - 0,98 $
Plage sur l'année
0,89 $ - 3,23 $
Capitalisation boursière
55,34 M USD
Volume moyen
313,11 k
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Actualités
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (USD) | juin 2024info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | — | — |
Charges d'exploitation | 1,97 M | -19,84 % |
Résultat net | -7,52 M | 10,17 % |
Marge bénéficiaire nette | — | — |
Bénéfice par action | — | — |
EBITDA | -5,69 M | 20,98 % |
Taux d'imposition effectif | — | — |
Bilan
Total des actifs
Total du passif
| (USD) | juin 2024info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 435,78 k | -91,55 % |
Total des actifs | 24,07 M | -25,53 % |
Total du passif | 15,60 M | -11,03 % |
Total des capitaux propres | 8,47 M | — |
Actions en circulation | 61,49 M | — |
Ratio cours/valeur comptable | 5,94 | — |
Rentabilité des actifs | -61,63 % | — |
Retour sur capitaux | -70,15 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (USD) | juin 2024info | Variation Y/Y |
|---|---|---|
Résultat net | -7,52 M | 10,17 % |
Trésorerie (opérations) | -4,58 M | 19,19 % |
Trésorerie (invest.) | -23,47 k | 88,08 % |
Trésorerie (financement) | -322,30 k | -133,87 % |
Variation nette en trésorerie | -4,92 M | -0,27 % |
Flux de trésorerie dispo. | -1,94 M | 32,46 % |
À propos
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
Date de fondation
mars 1983
Siège social
Site Web
Employés
43
